A case with intestinal lymphangiectasia successfully treated with slow-release octreotide

Digestive and Liver Disease

Volumn 36, Issue 10, 2004, Pages 687-690

  Filik, L ^a   Oguz, P ^a   Koksal, A ^a   Koklu, S ^a   Sahin, B ^a  

^a No 52/2 ^*  (Turkey)

Author keywords

Lymphangiectasia; Octreotide; Protein losing enteropathy

Indexed keywords

ALBUMIN; MEDIUM CHAIN TRIACYLGLYCEROL; OCTREOTIDE; GASTROINTESTINAL AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; CASE REPORT; CELIAC DISEASE; COMPRESSION THERAPY; DIARRHEA; DIET RESTRICTION; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FEMALE; GLUTEN FREE DIET; HOSPITAL DISCHARGE; HUMAN; INTESTINE LYMPHANGIECTASIA; LOW FAT DIET; LYMPHOCYTOPENIA; PROTEIN LOSING GASTROENTEROPATHY; SLOW RELEASE FORMULATION; DELAYED RELEASE FORMULATION; REVIEW; TREATMENT OUTCOME;

ADULT; DELAYED-ACTION PREPARATIONS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; LYMPHANGIECTASIS, INTESTINAL; OCTREOTIDE; TREATMENT OUTCOME;

EID: 16644401560     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2004.06.002     Document Type: Article

References (19)

1. Brasitus TA, Bissonnette BM. Protein losing enteropathy. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Gastrointestinal and liver disease. 6th ed. Philadelphia: W.B. Saunders; 1998. p. 371-3.
2. Donzelli F, Norberte L, Marigo A, Barbato A, Tapparello G, Basso G. Primary intestinal lymphangiectasia. Comparison between endoscopic and radiological findings. Helv Pediatr Acta 1994;35:169.
3. Rossi P, Covarelli P, Cirocchi R, Goracci G, Bartoletti MC, Fabbri C. Intestinal lymphangiectasis in adults. G Chir 1996;17:171-4.
4. Klingenberg RD, Homann N, Ludwig D. Type I intestinal lymphangiectasia treated successfully with slow-release octreotide. Dig Dis Sci 2003;48:1506-9.
5. Takahashi H, Imai K. What are the objectives of treatment for intestinal lymphangiectasia? J Gastroenterol 2001;36:137-8.
6. Perisic VN, Kokai G. Coeliac disease and lymphangiectasia. Arch Dis Child 1992;67:134-6.
7. Biagi F, Corazza GR. Clinical features of coeliac disease. Dig Liver Dis 2002;34:225-8.
8. Martucci S, Biagi F, Di Sabatino A, Corazza GR. Coeliac disease. Dig Liver Dis 2002;34:S150-153.
9. Nazer HM, Abutalib H, Hugosson C, al-Mahr M, Ali MA. Intestinal lymphangiectasia masquerading as coeliac disease. Ann Trop Paediatr 1991;11:349-55.
10. Dayal Y, DeLellis R, Celiac sprue. In: Cotran R, Kumar V, Robbins SL, editors. Robbins pathologic basis of disease. 4th ed. Philadelphia: W.B. Saunders; 1989. p. 877.
11. Curran RC, Colour atlas of histopathology. 3rd ed. Oxford University Press; 1988. p 71.
12. Mine K, Matsubayashi S, Nakai Y, Nakagawa T. Intestinal lymphangiectasia markedly improved with antiplasmin therapy. Gastroenterology 1989;96:1596-9.
13. MacLean JE, Cohen E, Weinstein M. Primary intestinal and thoracic lymphangiectasia: a response to antiplasmin therapy. Pediatrics 2002;109:1177-80.
14. Kuroiwa G, Takayama T, Sato Y, Takahashi Y, Fujita T, Nobuoka A. Primary intestinal lymphangiectasia successfully treated with octreotide. J Gastroenterol 2001;36:129-32.
15. Ballinger AB, Farthing MJ. Octreotide in the treatment of intestinal lymphangiectasia. Eur J Gastroenterol Hepatol 1998;10:699-702.
16. Bac DJ, van Hagen PM, Postema PTE, Ten Bokum AMC, Zondervan PE, van Blankenstein M. Octreotide for protein losing enteropathy with intestinal lymphangiectasia. Lancet 1995;345:1639.
17. Pawlikowski M, Melen-Mucha G. Perspectives of new potential therapeutic applications of somatostatin analogs. Neuroendocrinol Lett 2003;24:21-7.
18. Reynaert H, Geerts A. Pharmacological rationale for the use of somatostatin and analogues in portal hypertension. Aliment Pharmacol Ther 2003;18:375-86.
19. Goyal A, Smith NP, Jesudason EC, Kerr S, Losty PD. Octreotide for treatment of chylothorax after repair of congenital diaphragmatic hernia. J Pediatr Surg 2003;38:E19-20.